Barriers and facilitators to buprenorphine use for opioid agonist treatment: protocol for a scoping review

INTRODUCTION: In the context of the opioid crisis in North America, the benefits of evidence-based opioid agonist treatments such as buprenorphine/naloxone have not been optimised due to low uptake. Numerous factors contribute to the underuse of buprenorphine, and theory-informed approaches to ident...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMJ Open
Autors principals: Leece, Pamela, Khorasheh, Triti, Corace, Kimberly, Strike, Carol, Bayoumi, Ahmed M, Taha, Sheena, Marks, Elisabeth, Pach, Beata, Ahamad, Keith, Grennell, Erin, Holowaty, Melissa, Manson, Heather, Straus, Sharon E
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2019
Matèries:
Addiction
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6924699/
https://ncbi.nlm.nih.gov/pubmed/31843837
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2019-032285
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars